Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 11Colorectal Neoplasms 7Gastrointestinal Neoplasms 3Colonic Neoplasms 3Rectal Neoplasms 2Cholangiocarcinoma 2Untreated Resectable Pancreatic Adenocarcinoma 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Resectable 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Klatskin Tumor 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Sorafenib 68Bevacizumab 44Oxaliplatin 25Doxorubicin 22Gemcitabine 21Fluorouracil 21Radiosurgery 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17lenvatinib 17Cisplatin 17Capecitabine 17atezolizumab 14Leucovorin 14Hepatectomy 14Radiotherapy 12tremelimumab 10Irinotecan 10Drug Therapy 10Cyclophosphamide 10Carboplatin 10Blood Specimen Collection 10Ipilimumab 9regorafenib 8Liver Transplantation 8Everolimus 8Cryosurgery 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × Hydroxychloroquine × Gastrointestinal × Clear all
NCT03037437 2025-09-04

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
64 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡